Page last updated: 2024-08-23

nicorandil and Congenital Hyperinsulinism

nicorandil has been researched along with Congenital Hyperinsulinism in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gao, G; Guo, D; Li, YX; Liu, H; Liu, Y; Nasir, A; Ruzi, A; Wu, F; Xu, G; Yang, F	1

Other Studies

1 other study(ies) available for nicorandil and Congenital Hyperinsulinism

Article	Year
Modeling Congenital Hyperinsulinism with ABCC8-Deficient Human Embryonic Stem Cells Generated by CRISPR/Cas9. Scientific reports, 2017, 06-09, Volume: 7, Issue:1 Topics: C-Peptide; Cell Differentiation; Congenital Hyperinsulinism; CRISPR-Cas Systems; Gastrointestinal Agents; Gene Editing; Human Embryonic Stem Cells; Humans; Insulin; Insulin Antagonists; Insulin-Secreting Cells; Models, Biological; Nicorandil; Nifedipine; Octreotide; Phenotype; Potassium Chloride; Sulfonylurea Receptors; Vasodilator Agents	2017

Article

Year

Modeling Congenital Hyperinsulinism with ABCC8-Deficient Human Embryonic Stem Cells Generated by CRISPR/Cas9.

Scientific reports, 2017, 06-09, Volume: 7, Issue:1

Topics: C-Peptide; Cell Differentiation; Congenital Hyperinsulinism; CRISPR-Cas Systems; Gastrointestinal Agents; Gene Editing; Human Embryonic Stem Cells; Humans; Insulin; Insulin Antagonists; Insulin-Secreting Cells; Models, Biological; Nicorandil; Nifedipine; Octreotide; Phenotype; Potassium Chloride; Sulfonylurea Receptors; Vasodilator Agents

2017